维多珠单抗治疗溃疡性结肠炎患者的长期疗效与安全性meta分析OA

Objective To evaluate the efficacy and safety of long-term use of Vedolizumab(VDZ)in patients with ulcerative colitis(UC).Methods The randomized controlled trials were searched in Pubmed,Embase,ClinicalKey,Cochrane Library and Google Scholar databases,from the establishment of the database to June 30,2023,patients with UC in remission stage were taken as the research object,VDZ was used as the intervention condition,and the search language was limited to English.Results A total of 7 randomized controlled trials were finally included.Compared with the control group,patients with UC in remission stage could obtain higher clinical remission rate with VDZ(RR=2.60,95%CI[1.92,3.52]),clinical response rate(RR=2.21,95%CI[1.75,2.78]),mucosal healing rate(RR=2.51,95%CI[1.93,3.26]),lasting clinical remission rate(RR=2.42,95%CI[1.88,3.12]),corticosteroid-free remission rate(RR=3.23,95%CI[1.94,5.36]),with statistically significant differences(P<0.05).In terms of adverse events(RR=1.00,95%CI[0.91,1.10])or serious adverse events(RR=0.97,95%CI[0.72,1.29]),there were no statistically significant differences between the two groups(P>0.05).Conclusion VDZ can make patients with UC get long-term endoscopic mucosal healing with few ADRs,which is suitable for long-term use in clinical patients with UC.